fig1
![Treatment of epidermal growth factor receptor mutations in non-small cell lung cancer: current role and the future perspective](https://image.oaes.cc/9de4a343-d1c4-4431-b479-ea3afd301a52/1940.fig.1.png)
Figure 1. EGFR mutations identified in NSCLC.(A) Mutations associated with sensitivity to TKIs (top) andmutations associated with resistance to TKIs (bottom); (B) mutations isolated from NSCLC tumors with unclear association with response to erlotinib or gefitinib. X: multiple substitutions have been reported at an amino acid; P: P-loop; A: activation domain; α-C: α-C helix domain; EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinases inhibitor